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OBJECTIVES We hypothesized that, although the effects of dipyridamole and dobutamine on myocardial
blood volume (MBV) and mean microbubble velocity (VEL) are different, the magnitude of
perfusion deficit during both forms of stress is the same because both drugs unmask abnormal
myocardial blood flow (MBF) reserve.
BACKGROUND Both dipyridamole and dobutamine are used clinically as pharmacologic stress agents to
induce reversible perfusion defects in patients with chronic coronary artery disease (CAD),
but the basis for doing so for dobutamine is not clear.
METHODS Eleven chronically instrumented closed-chest dogs with multivessel coronary stenosis were
studied. Hemodynamics, radiolabeled microsphere-derived MBF, and myocardial contrast
echocardiography (MCE)-derived myocardial perfusion were measured at rest, after dipyrid-
amole infusion (0.56 mg·kg1), and at peak dobutamine dose (either 30 or
40 g·kg1·min1). Abnormal beds were defined as those demonstrating an MBF reserve3
with dipyridamole.
RESULTS In the presence of either drug, MBV increased more in the normal bed than in the abnormal
bed, but the increase was higher in both beds with dobutamine than with dipyridamole. The
slope of the relationship between MBF reserve and MBV reserve was greater during
dobutamine than dipyridamole (p 0.05). The converse was true for VEL reserve (p 0.05).
Consequently, the relationship between the ratios of either variable, or the product of the two,
between the abnormal bed and normal bed was similar for both drugs.
CONCLUSIONS Although the effects of dipyridamole and dobutamine on MBV and VEL are different, both
are equally effective in detecting physiologically relevant coronary stenoses on MCE. Both can
therefore be used interchangeably with myocardial perfusion imaging for the detection of
CAD. (J Am Coll Cardiol 2002;40:167–74) © 2002 by the American College of
Cardiology Foundation
Resting myocardial blood flow (MBF) remains normal even
when coronary arterial luminal diameter is narrowed to
approximately 85% (1). Consequently it may not be possible
to detect even a severe coronary stenosis at rest using
myocardial perfusion imaging. Unlike resting MBF, how-
ever, MBF reserve (defined as the ratio of hyperemic vs.
resting MBF) becomes compromised at 50% stenosis (1).
Therefore, regions subtended by vessels with 50% to 85%
stenosis demonstrate a reduced MBF reserve that results in
a reversible perfusion defect during stress and forms the
basis of coronary stenosis detection on non-invasive myo-
cardial perfusion imaging (1).
In addition to exercise, pharmacologic stress is being
increasingly used for the detection of coronary stenosis
(2–13). Historically, coronary vasodilators, which increase
MBF by their direct action on arteriolar smooth muscle,
have been used to induce reversible perfusion defects during
pharmacologic stress (2–4). More recently, however, cat-
echolamines (particularly dobutamine) have also been used
for inducing reversible perfusion defects (5–7). These agents
increase MBF by increasing myocardial oxygen demand
(14) and are thought to cause perfusion defects in the
presence of coronary stenoses from a lack of increase in
MBF compared with a bed supplied by a normal coronary
artery.
The purpose of this study was to test the hypothesis that,
whereas the effects of dipyridamole and dobutamine on
myocardial blood volume (MBV) and myocardial micro-
bubble velocity (VEL) are different, both drugs are equally
effective in detecting physiologically significant coronary
stenoses with myocardial perfusion imaging. We tested this
hypothesis in a closed-chest canine model of multivessel
chronic coronary stenoses between one and two weeks after
ameroid constrictor placement on the epicardial coronary
arteries and their major branches, at a time when resting
MBF is normal but MBF reserve may be reduced (15–17).
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METHODS
Animal preparation. The study protocol was approved by
the Animal Research Committee at the University of
Virginia and conformed to the American Heart Association
Guidelines for the Use of Animals in Research. Eleven adult
mongrel dogs were used in this study. They were given
75 mg of aspirin daily starting three days before surgery,
which was continued until euthanasia. Gentamicin (80 mg)
and cefazolin (1 g) were administered intravenously just
prior to surgery, and the latter was given twice daily for five
days after surgery.
Surgery was performed in a sterile operating room.
Anesthesia was induced with 300 g·kg1 of diazepam,
20 g·kg1 of fentanyl, and 400 g·kg1 of etomidate
administered intravenously and was maintained with a
mixture of 1% to 1.5% isoflurane, oxygen, and air. A 6-Fr
indwelling catheter was placed in a femoral artery through a
groin incision and was used for arterial pressure monitoring
as well as withdrawal of samples for radiolabeled micro-
sphere (RM)-derived MBF analysis. The catheter end was
capped with a rubber injection port and buried subcutane-
ously.
Skeletal muscle paralysis was induced with 300 g·kg1
of atracurium, and a left lateral thoracotomy was performed.
The proximal portions of the left anterior descending
coronary artery (LAD) and left circumflex coronary artery
(LCx), as well as any large branches of these arteries, were
dissected free from the surrounding tissue. Up to four
appropriately sized ameroid constrictors were placed around
all the vessels. A 6-Fr indwelling catheter was secured in the
left atrium, capped off with a rubber injection port, and
buried subcutaneously in the dorsum. This catheter was
used to inject RMs and measure left atrial pressure. The
chest was closed, and the animal was allowed to recover.
Myocardial contrast echocardiography. Myocardial con-
trast echocardiography (MCE) was performed using Defin-
ity (Bristol Myers Squibb Medical Imaging, North Billerica,
Massachusetts), which consists of microbubbles containing
a mixture of air and octafluorane in a bilayer phospholipid
shell (18). A 3% solution of this agent was administered as
a continuous infusion via a peripheral vein at a rate of 2
ml·min1 that resulted in adequate myocardial opacification
without shadowing of far-field structures. After steady state
was reached (2 min), imaging was started.
Intermittent harmonic imaging was performed using a
phased-array system (High Definition Imaging 3000cv,
Phillips) with ultrasound transmitted at 1.67 MHz and
received at 3.3 MHz. Left ventricular (LV) short-axis
images were acquired from the right thorax at the upper and
lower papillary muscle levels. Care was taken to obtain the
same views at every stage in each dog. A maximum dynamic
range of 60 dB was used. The mechanical index was set at
1.1, and the focal point was set at the level of the posterior
pericardium.
Ultrasound emission was gated to the electrocardiogram.
Dual triggering was used to obtain pulsing interval (PI) 1
cardiac cycle, where the “bubble destruction” trigger was set
to different intervals before the “imaging” trigger (18). The
“imaging” trigger was always set to end-systole, and images
acquired by this trigger were used for analysis. The PI was
progressively increased from 150 ms to 20 s. Up to eight
end-systolic images were acquired at each PI and recorded
on 0.5-in videotape with an S-VHS recorder.
Data were transferred from videotape to an off-line
computer with custom-designed software (19). Five images
acquired at each PI were aligned using computer cross-
correlation. Large transmural regions of interest were placed
over the LAD and LCx regions with care taken to avoid the
specular endocardial and epicardial borders. Myocardial
video intensity (VI) in each myocardial region at each PI
was automatically measured from the aligned and averaged
images for that PI.
A background image was obtained for each plane by
averaging VI from 4 or 5 pre-contrast frames. The VI in
each myocardial region within this image was then sub-
tracted from the averaged VI values obtained within the
same regions from averaged contrast-enhanced images for
each PI. Background-subtracted PI versus VI plots were
generated and were fitted to an exponential function: y  A
(1  et), where y is VI at PI t, A is the plateau VI
representing MBV, and  is the rate of rise of VI denoting
mean VEL. The product A· provides an index of MBF
(18). In addition, background-subtracted images at each PI
were also color-coded (19).
RM-derived MBF measurements. Approximately 2·106
11-m RMs (Bristol Myers Squibb Medical Imaging) were
suspended in 4 ml of normal saline–0.01% Tween 80
solution and injected into the left atrium over 20 s. Refer-
ence samples were withdrawn from the femoral artery over
130 s with a constant rate withdrawal pump (model 944,
Harvard Apparatus, Natick, Massachusetts). The postmor-
tem LV heart slice (see the following text), corresponding to
the MCE short-axis images, was cut into 16 wedge-shaped
pieces. Each piece was further divided into epicardial,
mid-myocardial, and endocardial portions. The tissue and
arterial reference samples were counted in a well counter
with a multichannel analyzer (Model 1282, LKB Wallac,
Abbreviations and Acronyms
LAD  left anterior descending coronary artery
LCx  left circumflex coronary artery
LV  left ventricular
MBF  myocardial blood flow
MBV  myocardial blood volume
MCE  myocardial contrast echocardiography
PI  pulsing interval
RM  radiolabeled microsphere
VEL  myocardial microbubble velocity
VI  myocardial video intensity
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Washington, DC). Corrections were made for activity
spill-over from one window to the next (20).
The MBF to each sample was calculated by the equation:
Qm  (Cm·Qr)/Cr where Qm  flow (ml·min
1), Cm 
tissue counts, Qr  rate of arterial blood withdrawal
(ml·min1) and Cr  counts in the reference sample (20).
Transmural MBF (ml·min1·g1) to each segment was
derived by dividing the sum of MBF to individual segments
by their combined weight. Transmural MBF within each
LV region (septal, anterior, lateral, and inferior) was calcu-
lated by averaging the transmural MBF in the segments
from that region. Endocardial MBF and epicardial MBF
were also calculated for each bed in the same manner. The
interventricular septal and anterior regions were assigned to
the LAD bed while the lateral and inferior were assigned to
the LCx bed.
Experimental protocol. Data were acquired in closed-
chest dogs between 7 and 10 days following surgery after
they were completely recovered. They were heavily sedated
with 20 mg·kg1 of fentanyl and 300 mg·kg1 of etomidate
and were placed on their left side, paralyzed with 300
g·kg1 of atracurium, intubated, and ventilated on room
air.
Hemodynamics (mean aortic and left atrial pressures, and
heart rate) as well as MCE and MBF data were obtained
both at rest and during pharmacologic stress induced with
dipyridamole (0.56 mg·kg1) administered intravenously
over 4 min. Data acquisition was initiated 5 min after
completion of dipyridamole infusion. One hour later, do-
butamine was infused intravenously at an initial dose of
5 g·kg1·min1 and increased at 4-min intervals to 10, 20,
and 30 g·kg1·min1. If the heart rate was not sufficiently
elevated at 30 g·kg1·min1 (140 beats/min), then the
dose was increased to 40 g·kg1·min1. Atropine was
not used to increase the heart rate, even if it was
140 beats/min at the peak dobutamine dose. Although
hemodynamic data were acquired at each dose of dobut-
amine, MCE was performed and RMs were injected only
during the peak dose, which was continued until all data
were obtained.
The dogs were euthanized with an overdose of pentobar-
bital and potassium chloride. Needles were inserted through
the heart to demarcate the ultrasound scanning planes, and
the heart was excised and sliced at these levels for postmor-
tem tissue analysis. Prior to analysis of MBF, the slices were
stained with 1.3% 2,3,5 triphenyl tetrazolium chloride
(Sigma Corp., St. Louis, Missouri) to assess for the presence
or absence of infarction (21).
Statistical methods. Data are expressed as mean  1 SD.
Comparisons between more than two stages were made
using repeated measures analysis of variance combined with
a post-hoc Tukey test. Comparisons between two stages
were performed using the Student t test. Correlations were
tested using least-squares fit linear regression analysis.
Differences were considered significant at p  0.05 (two-
sided).
RESULTS
Postmortem, no heart slice showed evidence of infarction on
tissue staining. Dipyridamole caused mild systemic hypo-
tension and reflex tachycardia compared with baseline
(Table 1). As expected, incremental doses of dobutamine
caused increases in heart rate and double product without
affecting systemic pressure.
MBF and regional myocardial perfusion. The RM-
derived MBF reserve was calculated by dividing the values
obtained during maximal hyperemia by those obtained at
rest, as were MCE-derived A, , and A· reserve. The LAD
and LCx beds in individual dogs were defined as normal or
abnormal based on an MBF reserve value of 3 measured
after dipyridamole administration. Because of artifacts, one
and six beds respectively, could not be analyzed for MCE
during dipyridamole and dobutamine administrations.
Table 2 depicts the effects of dipyridamole and dobut-
amine on MBF and MCE parameters. Both transmural
MBF and endocardial MBF were normal in all beds at rest.
Both the plateau VI, A (representing MBV) and the rate of
change of VI,  (representing VEL) were also similar in all
beds at rest, as was the product A·. There were no
differences in these parameters in the LAD versus the LCx
beds.
In the presence of either drug, A increased more in the
normal than in the abnormal bed, but the increase in A
was higher in both beds with dobutamine than with
dipyridamole. Thus the ratio of A between abnormal and
normal beds was equivalent for both drugs and produced
perfusion defects of equal magnitude (Fig. 1). As shown in
Figure 2, the relationship between RM-derived MBF re-
serve and MCE-derived A ratio was good in the presence of
either drug. The slope of the relationship between
microsphere-derived MBF reserve and MCE-derived A
reserve, however, was significantly greater (p  0.05) with
dobutamine than dipyridamole, indicating greater capillary









Resting 76  18 87  14 67  22
Dipyridamole
0.56 mgkg1
104  15* 74  11* 77  15
Dobutamine
5 gkg1min1
85  17 85  12 73  21
Dobutamine
10 gkg1min1
99  15 90  11 89  19
Dobutamine
20 gkg1min1
120  14† 92  13 111  23†
Dobutamine
30 gkg1min1
129  15† 97  13 125  26†
Dobutamine
40 gkg1min1
144  15†‡ 89  11 129  16†
*p  0.05 compared with resting using Student’s t test; †p  0.05 compared with
resting and dipyridamole based on repeated analysis of variance; ‡p  0.05 compared
with 20 gkg1 of dobutamine based on repeated analysis of variance.
AoP  mean aortic pressure; Double Product  (HR  AoP)/100; HR  heart
rate.
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recruitment with dobutamine than with dipyridamole for an
equivalent increase in MBF.
Whereas A increased more with dobutamine for both
beds,  increased more with dipyridamole (Table 2). Figure
3 illustrates the relationship between RM-derived MBF
reserve and MCE-derived  reserve for both drugs. In
contrast to MCE-derived A reserve, the slope of the
relationship between microsphere-derived MBF reserve and
MCE-derived  reserve was significantly less (p  0.01)
with dobutamine than dipyridamole, indicating a greater
increase in VEL with dipyridamole than dobutamine for the
same increase in MBF. However, no significant difference
in the ratio of  between the abnormal and normal beds for
the two drugs was found (Fig. 4).
The product A· tended to be lower in the abnormal than
in the normal bed even at baseline, although this did not
reach statistical significance. The relationship between
MBF ratio and A· ratio between the two beds was similar
during dipyridamole and peak dobutamine dose (Fig. 5). No
differences were found between MCE- and RM-derived
MBF reserve for either drug (Table 2), and the relationship
between MCE- and RM-derived MBF reserve for both
drugs was also similar (Fig. 6).
The reproducibility errors (estimated from the aggregate
standard deviation from all stages) for A,  and A· were
8.0  2.9%, 9.3  2.7% and 7.2  2.3%, respectively.
DISCUSSION
Vasodilators versus catecholamines. Pharmacologic stress
testing has been used for almost two decades for the
detection of coronary stenosis (2–13). Historically, coronary






Normal bed (transmural MBF reserve 3)
Transmural MBF (mlg1min1) 1.1  0.6 4.1  1.3* 3.7  1.1*
Endocardial MBF (mlg1min1) 1.1  0.4 3.5  1.5* 3.2  1.0*
A 28  6 43  11* 53  15*†
 5.1  1.0 11.0  4.3* 6.7  2.0†
A 144  37 494  281* 352  144*
Abnormal bed (transmural MBF reserve 3)
Transmural MBF (mlg1min1) 1.1  0.5 2.6  1.2* 2.4  1.2*
Endocardial MBF (mlg1min1) 1.1  0.3 2.0  1.0* 1.8  0.9*
A 28  5 31  8 38  12*†
 4.6  1.1 9.6  3.4* 5.4  2.2†
A 127  29 304  141* 209  118*†
Ratio between abnormal versus normal bed
Transmural MBF 1.0  0.2 0.7  0.2* 0.6  0.3*
Endocardial MBF 1.0  0.1 0.6  0.2* 0.6  0.2*
A 1.0  0.2 0.7  0.2* 0.7  0.2*
 0.9  0.4 0.8  0.2 0.8  0.3
A 0.9  0.2 0.6  0.4* 0.6  0.3*
*p  0.05 compared wtih baseline; †p  0.05 compared with dipyridamole; both using repeated measures analysis of variance.
MBF  myocardial blood flow; MCE  myocardial contrast echocardiography.
Figure 1. Relationship of the ratio of myocardial blood flow (MBF) between abnormal and normal beds (those with transmural MBF reserve of 3 and
3, respectively, x-axis) during dipyridamole (filled circles) and dobutamine (open circles) versus ratio myocardial blood volume (A) from the two beds
(y-axis).
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vasodilators have been used to induce reversible perfusion
defects during myocardial perfusion imaging (2–4), while
both vasodilators and catecholamines (particularly dobut-
amine) have been used to produce reversible regional dys-
function on LV functional imaging (8–13). More recently,
however, dobutamine has also been used for assessment of
myocardial perfusion (5–7). Although studies have been
performed to compare the physiologic basis for using
dobutamine and dipyridamole for inducing regional LV
dysfunction (22), the physiologic basis for the use of
dobutamine for inducing reversible perfusion defects is
unclear.
Unlike other imaging modalities that can either measure
MBF (such as positron emission tomography [23]) or
measure relative MBV (such as single photon imaging [6,7],
X-ray, and magnetic resonance imaging), MCE can mea-
sure both components of flow: MBV and VEL (18).
Therefore, it is ideally suited for determining the mecha-
nism of reversible perfusion defects. Conventional wisdom
indicates that a reversible defect on myocardial perfusion
imaging occurs from flow disparity produced between re-
gions subtended with normal as compared with stenotic
arteries during stress (1). We have recently shown this not
to be the case. The reason for reversible perfusion defects in
the presence of vasodilator stress is a decrease in MBV that
occurs secondary to capillary derecruitment (24). Because
the pressure distal to a stenosis decreases when flow through
it is increased, the capillaries increase their resistance in
order to maintain a constant hydrostatic pressure that is
essential for homeostasis. Since capillaries do not have
smooth muscle, they can increase their total resistance only
by derecruitment (24). The lower number of capillaries
results in a perfusion defect on MCE. The same phenom-
enon is seen with radioisotopes because of the smaller
surface area for isotope extraction (25).
We have previously shown that in the absence of systemic
hemodynamic effects during direct administration of aden-
osine into the normal coronary circulation, VEL increases in
proportion to the increase in MBF with no change in MBV
(18). Thus, there is no capillary recruitment, and increases
in flow are mediated solely by increases in VEL. This is to
be expected because capillary recruitment is not required
when myocardial O2 demand remains unchanged.
More recently, we have shown that MBV also remains
Figure 2. Relationship between radiolabeled microsphere-derived myocardial blood flow (MBF) reserve (x-axis) and myocardial contrast echocardiography-
derived A reserve (y-axis) in the presence of dipyridamole (filled circles) and dobutamine (open circles).
Figure 3. Relationship between radiolabeled microsphere-derived myocardial blood flow (MBF) reserve (x-axis) and myocardial contrast echocardiography-
derived  reserve (y-axis) in the presence of dipyridamole (filled circles) and dobutamine (open circles).
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unchanged with mild increases in myocardial O2 demand
induced by either pacing or low-dose dobutamine (26). The
mild increase in flow is caused by an increase in VEL. With
greater increases in myocardial O2 demand that occurs with
higher doses of dobutamine, however, MBV increases and
can double at high levels of MBF (26). Therefore, increased
myocardial O2 demand is a prerequisite for increases in
MBV during stress. This can also occur with a coronary
vasodilator, as noted in the present study, but only when the
double product is increased from tachycardia associated with
the systemic administration of these drugs. In fact, we have
demonstrated that an increase in myocardial O2 demand
may be imperative for induction of regional LV dysfunction
during dipyridamole stress in the presence of coronary
stenosis because it unmasks the underlying reduced endo-
cardial MBF reserve in this situation (27).
As expected, we found that for the same increase in
MBF, MBV is higher with dobutamine than dipyridamole,
whereas the converse is true for VEL. Interestingly, despite
these differences, the relative changes in both parameters
between beds showing an MBF reserve of 3 or 3 were
similar for both drugs. Thus it appears that dobutamine
increases MBV in all myocardial beds with noncritical
stenoses. Because of higher myocardial O2 demand, all beds
have more capillaries functioning with dobutamine than
with dipyridamole. But the beds with stenoses exhibit
relative capillary derecruitment just as they do with dipy-
ridamole. This relative decrease (or lack of increase) in
capillary number can also explain the occurrence of revers-
ible perfusion defects with dobutamine on radioisotope
imaging (6,7).
Comparison with previous studies. Similar to our results
in dogs, the magnitude of increase in MBF has been shown
to be similar in the normal myocardium of humans receiving
dobutamine-atropine and dipyridamole (23). Whereas no
experimental studies have compared the MCE findings for
dobutamine with the MCE findings for dipyridamole,
Lafitte et al. (28) compared dobutamine and adenosine.
There are several other major differences between our study
and theirs. Whereas they used an open-chest model in
Figure 4. Relationship of the ratio of myocardial blood flow (MBF) between abnormal and normal beds (those with transmural MBF reserve if 3 and
3, respectively, x-axis) during dipyridamole (filled circles) and dobutamine (open circles) versus ratio of  from the two beds (y-axis).
Figure 5. Relationship of the ratio of myocardial blood flow (MBF) between abnormal and normal beds (those with transmural MBF reserve if 3 and
3, respectively, x-axis) during dipyridamole (filled circles) and dobutamine (open circles) versus ratio of the product A· from the two beds (y-axis).
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which stenoses were created acutely, we used a closed-chest
model with chronic coronary stenoses. Unlike their study,
we had no critical stenoses—MBF was normal at rest in all
our dogs. The most important difference, however, may be
related to the method of imaging. Lafitte et al. (28) used
“real-time” low mechanical index imaging. The sensitivity
of this method is four to six times less than the high
mechanical index imaging used in the present study. The
dynamic range of their method is also threefold less. These
may be the reasons they were unable to detect the small
decreases in MBV that we saw with milder stenoses. They
also found adenosine to be less effective than dobutamine in
detecting milder stenoses, which may have been related to
less hyperemia produced by adenosine in their dogs.
Whereas we did not assess regional function in the
present study, Lafitte et al. (28) noted a lower sensitivity of
both dobutamine and adenosine for inducible LV regional
dysfunction in comparison to inducible perfusion defect.
We have also recently demonstrated that in demand isch-
emia caused by dobutamine, perfusion mismatch precedes
regional dysfunction—the so-called ischemic cascade (29).
We also showed that more than one myocardial region
exhibited perfusion mismatch in multivessel stenosis, while
this was not always the case with regional dysfunction.
Thus, it would seem that even with dobutamine, assessment
of myocardial perfusion may be better than assessment of
regional function. The same is of course true for coronary
vasodilators (9,28).
Study limitations. Transthoracic imaging in closed-chest
dogs can be challenging, but we have developed consider-
able experience with this model. Obtaining the same imag-
ing plane at several different stages can be difficult. There-
fore, we fixed the transducer at the same levels throughout
the study, and all stages were performed on the same
occasion. Registration of antemortem and postmortem data
is more difficult. We minimized errors by comparing post-
mortem heart slices to the images in each dog and selecting
the slices closest to the images for RM-derived MBF
analysis.
Because of tachycardia-induced image artifacts (which
are even more likely to occur with “real-time” methods), we
could not analyze 6 of the 44 myocardial regions during
dobutamine stress. Our inability to do so with dipyridamole
was much less (only one region). We did not find differences
in the MCE values derived from the LAD versus the LCx
beds, because we defocused the ultrasound beam by placing
the focal point on the posterior myocardium and by not
analyzing data in the 11 to 1 o’clock positions.
Clinical implications. Although our results show that
dobutamine and dipyridamole are comparable for detecting
coronary stenoses with quantitative MCE, in practical
terms, MCE in our hands is both technically and logistically
easier with dipyridamole than with dobutamine. The side
effects of dobutamine are also greater, as is the time required
for completion of a study. Another potential limitation of
dobutamine is that the increase in MBV in all beds might
mask any disparity in MBV that may occur between beds.
Therefore, the dose of contrast (as low as possible) and the
method of administration (continuous infusion rather than
bolus) are crucial (30). If the dose is high, signal saturation
will obscure any differences in MBV that are induced by the
drug. This is more likely to occur with a bolus injection than
with continuous infusion and with “real time” low mechan-
ical index than with intermittent high mechanical index
imaging.
We measured relative MBV and VEL in this study
(abnormal vs. normal bed) in a manner similar to nuclear
cardiology, where activity is measured in relative terms. In
theory, multivessel stenoses can be missed using this ap-
proach because the normal bed may itself be subtended by a
coronary stenosis. An advantage of MCE is that both MBV
and VEL can be measured in the same myocardial segment
before and after stress. So if a segment does not demonstrate
the required change in either MBV or VEL, it can be
termed abnormal. If this abnormality is regional, then
coronary stenosis can be suspected. More clinical studies are
required to define the role of both classes of pharmacologic
Figure 6. Relationship between radiolabeled microsphere-derived myocardial blood flow (MBF) reserve (x-axis) and myocardial contrast echocardiography-
derived A· reserve (y-axis) in the presence of dipyridamole (filled circles) and dobutamine (open circles).
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agents for the assessment of myocardial perfusion and the
detection of coronary stenoses with MCE.
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vascular Division, University of Virginia Medical Center, Box
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